West Pharma (WST) Tops Q1 EPS by 2c; Boosts Lower-End of FY16 Outlook

West Pharma (NYSE: WST) reported Q1 EPS of $0.53, $0.02 better than the analyst estimate of $0.51. Revenue for the quarter came in at $362.1 million versus the consensus estimate of $355.86 million.

GUIDANCE:

West Pharma sees FY2016 EPS of $2.12-$2.25, versus prior guidance of $2.10-$2.25 and the consensus of $2.18. West Pharma sees FY2016 revenue of $1.49-1.51 billion, versus prior guidance of $1.485-1.51 billion and the consensus of $1.50 billion.

For earnings history and earnings-related data on West Pharma (WST) click here.

You May Also Be Interested In

• AeroVironment restates quarterly financials, citing $89M goodwill error
• Pfizer lung cancer drug misses survival goal in Phase 3 trial
• JPMorgan Starts ICICI Prudential Asset Management (ICICIAMC:IN) at Overweight